June 2015 Corporate Fact Sheet -- a little outdated because we have some more good news since, but here it is:
http://cellceutix.com/wp-content/uploads/2015...ened-1.pdf
And here's the "new" news:
July 15, 2015 Kevetrin Receives FDA Orphan Drug Designation for Kevetrin for ovarian cancer
July 20, 2015 Brilacidin Phase 3 for ABSSSI verbally approved by FDA in meeting
Aug. 3, 2015 Ongoing enrollment, Phase 2 Brilacidin-OM
Aug. 6, 2015 Phase 2 Prurisol Trial Commences (psoriasis drug)
http://cellceutix.com/wp-content/uploads/2015...ened-1.pdf
And here's the "new" news:
July 15, 2015 Kevetrin Receives FDA Orphan Drug Designation for Kevetrin for ovarian cancer
July 20, 2015 Brilacidin Phase 3 for ABSSSI verbally approved by FDA in meeting
Aug. 3, 2015 Ongoing enrollment, Phase 2 Brilacidin-OM
Aug. 6, 2015 Phase 2 Prurisol Trial Commences (psoriasis drug)